Dated November 2, 2022 EQUITY PURCHASE AGREEMENT among REACTION BIOLOGY CORPORATION, as Purchaser VIVOPHARM PTY, LTD., as Seller VYANT BIO, INC., as Parent and VIVOPHARM, LLC, as the CompanyEquity Purchase Agreement • November 3rd, 2022 • Vyant Bio, Inc. • Services-medical laboratories • Delaware
This EQUITY PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 2, 2022 by and among Reaction Biology Corporation, a Pennsylvania corporation (“Purchaser”), vivoPharm, LLC, a Delaware limited liability company (the “Company”), vivoPharm Pty, Ltd., a private company organized under the laws of Australia and the sole member of the Company (“Seller”), and Vyant Bio, Inc., a Delaware corporation (“Parent”).
